SGLT-2 inhibition in IgA nephropathy: the new standard of care?

摘要

Despite supportive measures that slow the rate of progression of chronic kidney disease in IgA nephropathy, many patients still progress to end-stage kidney disease. Currently employed immunosuppressive strategies lack conclusive efficacy data, while there is evidence for treatment-emergent toxicity. A subanalysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease Trial, which encompassed 270 patients with a diagnosis of IgA nephropathy, now provides early evidence that dapagliflozin may be a safe and effective addition to current standard of care in IgA nephropathy.